



ONCE-DAILY XELJANZ® XR IS NOW APPROVED
FOR THE TREATMENT OF MODERATE TO SEVERE RA¹

חדש!

RA¹ למטופלי ביום פעם XELJANZ® XR 
[tofacitinib citrate]
extended release • 11 mg tablets



Pharmacokinetic equivalence

- XELJANZ XR 11 mg once daily is pharmacokinetically equivalent to XELJANZ 5 mg BID²
- Half-life is ~6 hours with XELJANZ XR 11 mg once daily and ~3 hours with XELJANZ 5 mg BID¹



How to take XELJANZ/XELJANZ XR

- Take orally with or without food. Swallow tablets whole and intact.
Do not crush, split, or chew¹
- Store below 30°C¹



Recommended dosing

- Patients treated with XELJANZ 5 mg BID may be switched to XELJANZ XR 11 mg once daily the day following the last dose of XELJANZ 5 mg³
- Both XELJANZ and XELJANZ XR can be taken with and without MTX. No dose adjustment of MTX is necessary when combined with XELJANZ/XELJANZ XR¹



**XELJANZ 5 mg
twice daily**



**XELJANZ XR 11 mg
once daily**

עם **XELJANZ® XR**  **הכדור בידיים שלך - פעם או פעמיים ביום (RA)¹**
[tofacitinib citrate]

SOME PATIENTS MAY REQUIRE DOSE ADJUSTMENTS DURING TREATMENT WITH XELJANZ®/XELJANZ XR¹

Dose adjustments for patients taking XELJANZ 5 mg BID or XELJANZ XR 11 mg once daily^{1,2}

	Laboratory Values confirmed by repeat testing within 7 days	Recommendations
Lymphocytes (cells/mm ³)	Lymphocyte count <500 (confirmed by repeat testing)	Discontinue treatment
Neutrophils (cells/mm ³)	ANC 500-1000	Interrupt dosing until ANC >1000
	ANC <500 (confirmed by repeat testing)	Discontinue treatment
Haemoglobin (g/dL)	Hb <9.0 or decrease >2 (confirmed by repeat testing)	Interrupt treatment until values have normalized

The following patients should be initiated on XELJANZ 5 mg once daily¹:

- Patients with severe renal insufficiency or moderate hepatic impairment
- Patients receiving potent inhibitors of cytochrome P450 (CYP3A4) (eg, ketoconazole) or receiving one or more concomitant medications that result in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (eg, fluconazole)

¹If drug-induced liver injury is suspected, the administration of XELJANZ/XELJANZ XR should be interrupted until this diagnosis has been excluded.¹
ANC=absolute neutrophil count; BID=twice daily; Hb=hemoglobin.

"XELine"

שירות אחיות טלפוני מבית פיזר למטופלי Xeljanz בכל האינדיקציות



ללא עלות



מענה בשפות: עברית, ערבית, רוסית ואנגלית



המענה ניתן ע"י צוות אחיות מוסמך ומנוסה



פעיל בימי א' - ה'
8:00-19:00 בשעות

09-9700561

REFERENCES

1. XELJANZ latest approved Israeli prescribing information.
2. Lamba M, Wang R, Fletcher T, Alvey C, Kushner J IV, Stock TC. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharmacol. 2016;56(11):1362-1371.

לפניות בנושא מידע רפואי: MIQueriesIsrael@pfizer.com
www.sideeffects.health.gov.il לדיווח תופעות לוואי למשרד הבריאות.
israelprodcomplaints@pfizer.com לדיווח תלונות איכות.

פיזור פרמצבטיקה ישראל בע"מ | שנקר 9, הרצליה פיתוח 4672509, טל': 09-970-0500, www.Pfizer.co.il



XELJANZ XR 
 [tofacitinib citrate]
 extended release • 11 mg tablets